·12 min read·compound-guide
Peptide pulse · May 2026: orforglipron approved, oral Wegovy live, RFK reclassification, and the 503B endgame
What actually shifted in the last 60 days: Foundayo (orforglipron) approved early under the National Priority Voucher, oral Wegovy 25mg shipping, FDA proposes excluding tirzepatide from 503B bulks, RFK pulled 14 peptides off Category 2, survodutide phase 3 obesity readout. Routing impact for each.